These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27075462)

  • 1. IL-23/IL-17 axis in spondyloarthritis-bench to bedside.
    Raychaudhuri SP; Raychaudhuri SK
    Clin Rheumatol; 2016 Jun; 35(6):1437-41. PubMed ID: 27075462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.
    Raychaudhuri SK; Saxena A; Raychaudhuri SP
    Clin Rheumatol; 2015 Jun; 34(6):1019-23. PubMed ID: 25939522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?
    Baeten D; Adamopoulos IE
    Front Immunol; 2020; 11():623874. PubMed ID: 33679714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies.
    Chyuan IT; Chen JY
    Mediators Inflamm; 2018; 2018():2403935. PubMed ID: 29670461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory pathways in spondyloarthritis.
    Hreggvidsdottir HS; Noordenbos T; Baeten DL
    Mol Immunol; 2014 Jan; 57(1):28-37. PubMed ID: 23969080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
    Toussirot E
    Inflamm Allergy Drug Targets; 2012 Apr; 11(2):159-68. PubMed ID: 22280236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-17 targeted therapies in axial spondyloarthritis.
    Wendling D
    Immunotherapy; 2015; 7(11):1125-8. PubMed ID: 26513376
    [No Abstract]   [Full Text] [Related]  

  • 8. Secukinumab: a promising therapeutic option in spondyloarthritis.
    Maldonado-Ficco H; Perez-Alamino R; Maldonado-Cocco JA
    Clin Rheumatol; 2016 Sep; 35(9):2151-61. PubMed ID: 27437696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of the IL-23/IL-17 Axis in Disease Initiation in Spondyloarthritis: Lessons Learned From Animal Models.
    Mandour M; Chen S; van de Sande MGH
    Front Immunol; 2021; 12():618581. PubMed ID: 34267743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritis.
    Cauli A; Mathieu A
    J Rheumatol Suppl; 2012 Jul; 89():15-8. PubMed ID: 22751583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spondyloarthritis and the Human Leukocyte Antigen (HLA)-B
    Kavadichanda CG; Geng J; Bulusu SN; Negi VS; Raghavan M
    Front Immunol; 2021; 12():601518. PubMed ID: 33763060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients.
    Milanez FM; Saad CG; Viana VT; Moraes JC; Périco GV; Sampaio-Barros PD; Goncalves CR; Bonfá E
    Arthritis Res Ther; 2016 Feb; 18():52. PubMed ID: 26912133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 is found in the synovium of psoriatic arthritis and spondyloarthritis, not in rheumatoid arthritis.
    Wong WM; Howell WM; Coy SD; Cawley MI; Smith JL
    Scand J Rheumatol; 1996; 25(4):239-45. PubMed ID: 8792801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis.
    Tsukazaki H; Kaito T
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis.
    Bowness P; Ridley A; Shaw J; Chan AT; Wong-Baeza I; Fleming M; Cummings F; McMichael A; Kollnberger S
    J Immunol; 2011 Feb; 186(4):2672-80. PubMed ID: 21248258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases.
    Chen S; Paveley R; Kraal L; Sritharan L; Stevens E; Dedi N; Shock A; Shaw S; Juarez M; Yeremenko N; Baeten D; Payne A
    J Autoimmun; 2020 Jul; 111():102435. PubMed ID: 32360069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-17 in spondyloarthritis: is the T-party over?
    Yeremenko N; Baeten D
    Arthritis Res Ther; 2011 Jun; 13(3):115. PubMed ID: 21722352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data.
    Sakkas LI; Bogdanos DP
    Autoimmun Rev; 2017 Jan; 16(1):10-15. PubMed ID: 27666819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate Cells: The Alternative Source of IL-17 in Axial and Peripheral Spondyloarthritis?
    Rosine N; Miceli-Richard C
    Front Immunol; 2020; 11():553742. PubMed ID: 33488572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.